We have located links that may give you full text access.
The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
BACKGROUND: Long-term management of intermediate- and high-risk differentiated thyroid cancer (DTC) involves thyrotropin (TSH) suppression with thyroid hormone to prevent potential stimulation of TSH receptors on DTC cells, leading to tumor growth. However, the current guidelines recommending TSH suppression are based on low-to-moderate quality evidence.
METHODS: We performed a systematic review and meta-analysis of studies evaluating the role of TSH suppression in intermediate- and high-risk DTC patients (≥18 years) treated as per regional guideline-based therapy with a follow-up duration of 5 years (PROSPERO #252396). TSH suppression was defined as 'below normal reference range' or, when known, <0.5 mIU/L. Primary outcome measures included A. composite of progression-free survival (PFS), disease-free survival (DFS), and relapse-free survival (RLFS), and B. composite of disease-specific survival (DSS), and overall survival (OS). Secondary outcome included a composite of cardiac or skeletal adverse events. All outcomes and comparisons were represented as TSH suppression versus TSH non-suppression. Randomized controlled trials, cohort studies, and case-control studies were included for analysis. Pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated using random-effects model.
RESULTS: Abstract screening was performed on 6,369 studies. After the exclusion of irrelevant studies and full-text screening, 9 studies were selected for the final meta-analysis. Based on 7 studies (3,591 patients), the composite outcome of PFS, DFS, and RLFS was not significantly different between TSH suppression and non-suppression groups (HR: 0.75; 95% CI: 0.48 - 1.17; I2=76%). Similarly, a DSS and OS composite outcome assessment based on 4 studies (3,616 patients) did not favor TSH suppression (HR: 0.69; 95% CI: 0.31 - 1.52; I2 = 88%). Even after excluding studies of lower quality, the primary outcomes were not significantly different between the TSH suppression and non-suppression cohorts. The secondary outcome, obtained from 2 studies (1,294 patients), was significantly higher in the TSH-suppressed groups (HR: 1.82; 95% CI: 1.30 - 2.55; I2 = 0%). Significant study heterogeneity was noted for primary outcomes.
CONCLUSION: TSH suppression in intermediate- and high-risk DTC may not improve survival outcomes but may increase the risk of secondary complications. However, the limited evidence and study heterogeneity warrant cautious interpretation of our findings.
METHODS: We performed a systematic review and meta-analysis of studies evaluating the role of TSH suppression in intermediate- and high-risk DTC patients (≥18 years) treated as per regional guideline-based therapy with a follow-up duration of 5 years (PROSPERO #252396). TSH suppression was defined as 'below normal reference range' or, when known, <0.5 mIU/L. Primary outcome measures included A. composite of progression-free survival (PFS), disease-free survival (DFS), and relapse-free survival (RLFS), and B. composite of disease-specific survival (DSS), and overall survival (OS). Secondary outcome included a composite of cardiac or skeletal adverse events. All outcomes and comparisons were represented as TSH suppression versus TSH non-suppression. Randomized controlled trials, cohort studies, and case-control studies were included for analysis. Pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated using random-effects model.
RESULTS: Abstract screening was performed on 6,369 studies. After the exclusion of irrelevant studies and full-text screening, 9 studies were selected for the final meta-analysis. Based on 7 studies (3,591 patients), the composite outcome of PFS, DFS, and RLFS was not significantly different between TSH suppression and non-suppression groups (HR: 0.75; 95% CI: 0.48 - 1.17; I2=76%). Similarly, a DSS and OS composite outcome assessment based on 4 studies (3,616 patients) did not favor TSH suppression (HR: 0.69; 95% CI: 0.31 - 1.52; I2 = 88%). Even after excluding studies of lower quality, the primary outcomes were not significantly different between the TSH suppression and non-suppression cohorts. The secondary outcome, obtained from 2 studies (1,294 patients), was significantly higher in the TSH-suppressed groups (HR: 1.82; 95% CI: 1.30 - 2.55; I2 = 0%). Significant study heterogeneity was noted for primary outcomes.
CONCLUSION: TSH suppression in intermediate- and high-risk DTC may not improve survival outcomes but may increase the risk of secondary complications. However, the limited evidence and study heterogeneity warrant cautious interpretation of our findings.
Full text links
Related Resources
Trending Papers
Hemodynamic Support in Sepsis.Anesthesiology 2024 June 2
The New Challenge of Obesity - Obesity-Associated Nephropathy.Diabetes, Metabolic Syndrome and Obesity 2024
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review.Seminars in Nephrology 2024 May 15
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app